News

Results from the Phase III MONeT clinical trial found that Abrysvo was well tolerated in adults over the age of 18 years old.

New investigators practicing in community-based settings bring enthusiasm and a fresh approach to clinical research, while also boosting collaboration and merging personal connection and patient-centric insights.

In part 1 of this video interview, Melissa Easy, VP commercial, digital products & solutions, IQVIA highlights how patients, sites, and sponsors can benefit from recent advancements such as AI and LLMs.

Designing eConsent for each study from a stakeholders’ value, not technology perspective.

Results represent the first positive Phase III clinical trial in a dry eye chamber with a symptom as the primary endpoint.

In the fourth and final part of this video interview, Vincent Keunen, founder & CEO of Andaman7 looks forward and highlights some potential advancements with the use of AI.

Induction therapy comprised of Sarclisa (isatuximab-irfc; Sanofi) plus lenalidomide, bortezomib, and dexamethasone significantly improved progression-free survival from first randomization in transplant-eligible patients with newly diagnosed multiple myeloma.

Overcoming saturation in the cell therapy landscape.

In part 3 of this video interview, Vincent Keunen, founder & CEO of Andaman7 shares his own experience as a patient when it comes to using digital applications.

Patients in the Keytruda (pembrolizumab)-vibostolimab combo plus chemotherapy arm experienced a higher rate of adverse events compared to those in the control arm.

Results show nipocalimab could address the high unmet need of patients with severe hemolytic disease of the fetus and newborn, which is a life-threatening and rare condition with no other therapies currently in clinical development.

In part 2 of this video interview, Vincent Keunen, founder & CEO of Andaman7 highlights how technology vendors should be keeping the patient in mind when building solutions.

In a presentation at the 2024 International Association for the Study of Pain World Congress, Concentric Analgesics shared positive Phase II data for its lead candidate.

Study shows efficacy of olanzapine in improving complete response rates and chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens comprised of oxaliplatin, carboplatin, or irinotecan.

In part 1 of this video interview, Vincent Keunen, founder & CEO of Andaman7 discusses how service providers and sponsors can make the lives of patients contributing to research easier.

Phase III study of Bayer’s non-steroidal, selective mineralocorticoid receptor antagonist met its primary endpoint.

Tremfya dosing at an interval of every 16 weeks was noninferior to the standard every eight weeks dosing interval for maintenance of psoriasis disease control.

In the fifth and final part of this video interview, Rama Kondru, PhD, CEO of Veridix AI looks forward to what the LLM landscape in clinical trials could look like in five years.

Phase III study of tirzepatide in adults with heart failure with preserved ejection fraction and obesity met all primary endpoints.

Multiple observational studies have shown that patients with cancer and a higher body mass index who were administered chemotherapy experienced improved survival compared to patients with normal body weight.

In part 4 of this video interview, Rama Kondru, PhD, CEO of Veridix AI discusses best practices for choosing the right artificial intelligence solutions.

Phase IV study finds antihypertensive therapy guided by ambulatory blood pressure monitoring improves target organ damage in patients with masked hypertension.

Giving sites and sponsors an effective tool for principled negotiations.

In part 3 of this video interview, Rama Kondru, PhD, CEO of Veridix AI touches on how large language models can leverage unstructured data.

Webinar Date/Time: Tuesday, August 27, 2024 at 11:00 AM EDT | 8:00 AM PDT | 4:00 PM BST | 5:00 PM CEST

The trial demonstrated clinically meaningful improvements in overall response rate and duration of response in its patient population.

Phase III DREAMM 7 trial data show median progression-free survival of 36.6 months with Blenrep (belantamab mafodotin), bortezomib, and dexamethasone compared to 13.4 months with Darzalex (daratumumab), bortezomib, and dexamethasone.

In part 2 of this video interview, Rama Kondru, PhD, CEO of Veridix AI highlights areas that large language models can be used in clinical trials including patient recruitment and retention.

According to the trial data, PGN-EDO51 is outperforming previously studied oligonucleotide therapies.

In part 1 of this video interview, Rama Kondru, PhD, CEO of Veridix AI discusses challenges with adoption and the potential uses of large language models in clinical trials.